Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of...

Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101 – Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field – – New SAB to complement...

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer   Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer    Richard Couch, formerly at Celgene,...

Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertiseAdding further oncology experience to Immodulon’s leadership team as...

Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the BoardGertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive OfficerPeter Greaney, formerly at ADC...